When should antiretroviral therapy be initiated in a patient with cytomegalovirus (CMV) retinitis, given the concern for immune reconstitution inflammatory syndrome (IRIS)?

When to Initiate Antiretroviral Therapy in CMV Retinitis

You should initiate ART immediately in patients with CMV retinitis—there is no need to delay, and the concern about IRIS causing harm is not supported by evidence. 1

The Evidence is Clear: Start ART Without Delay

The CDC/NIH/IDSA guidelines explicitly state: "No data are available to demonstrate that starting ART among treatment-naïve patients with CMV retinitis would have an adverse effect on retinitis" 1. This directly contradicts the common misconception that ART should be delayed due to IRIS concerns.

Key Recommendations:

For CMV Retinitis (and GI/Pulmonary CMV Disease):

• Initiate ART immediately alongside anti-CMV therapy 1
• Do NOT delay ART initiation
• The mortality benefit from both ART and anti-CMV therapy outweighs theoretical IRIS risks

The Only Exception - CMV Neurologic Disease:

• Consider delaying ART until clinical improvement occurs (typically within 2-4 weeks of starting anti-CMV therapy) 1
• Rationale: Localized inflammatory reactions in the CNS could cause significant morbidity
• This is a prudent precaution (CIII recommendation), not based on evidence of harm, but rather theoretical concern

The Treatment Algorithm

Step 1: Diagnose CMV Retinitis

• Dilated indirect ophthalmoscopy by experienced ophthalmologist
• Document lesion location and severity

Step 2: Initiate Anti-CMV Therapy Immediately

Choice depends on lesion location:

• Sight-threatening lesions (zone 1: adjacent to optic nerve or fovea): Ganciclovir intraocular implant + oral valganciclovir 1
• Small peripheral lesions: Oral valganciclovir alone may be adequate 1
• Consider intravitreal ganciclovir injection at diagnosis for immediate high local concentration 1

Step 3: Start ART Simultaneously

• Do not wait for completion of CMV induction therapy
• Use standard first-line ART regimens (integrase inhibitor-based preferred) 2
• Anti-CMV therapy decreases mortality in immunocompromised patients with CMV retinitis 1

Step 4: Monitor for Immune Recovery Uveitis (IRU)

• IRU is the actual IRIS manifestation, not worsening retinitis
• Occurs 4-12 weeks after ART initiation in patients with substantial CD4+ rise 1
• Presents as anterior chamber or vitreous inflammation, NOT progressive retinitis
• Treat with periocular or systemic corticosteroids if it occurs 1

Why the Confusion Exists

Common Pitfall: Clinicians confuse immune recovery uveitis (IRU) with progressive retinitis. Research shows that among patients who achieve immune recovery after starting ART, there is neither increased rate of new-onset CMV retinitis nor worsening of existing retinitis in the first 6 months 3. The inflammatory response (IRU) is manageable and does not justify delaying life-saving ART.

The Reality: Active CMV retinitis can persist for months after ART initiation if anti-CMV therapy is not given 4. This is why both therapies must be started together—ART alone takes 3-6 months to provide sufficient immune recovery to control retinitis 1.

Critical Points

• Mortality benefit: Anti-CMV therapy decreases mortality in patients with CMV retinitis and immune compromise 1
• Vision preservation: Delaying treatment risks irreversible vision loss
• IRU is treatable: When it occurs, it responds to corticosteroids with ~50% response rate 1
• Close monitoring required: Monthly ophthalmologic follow-up during anti-CMV treatment 1

Bottom line: The outdated practice of delaying ART in CMV retinitis is not evidence-based and potentially harmful. Start both anti-CMV therapy and ART immediately to optimize both survival and vision outcomes.